Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Aug 7;25(29):3897-3919.
doi: 10.3748/wjg.v25.i29.3897.

Consensus on management of hepatitis C virus infection in resource-limited Ukraine and Commonwealth of Independent States regions

Massimo Giuseppe Colombo  1 , Erkin Isakovich Musabaev  2 , Umed Yusupovich Ismailov  3 , Igor A Zaytsev  4 , Alexander V Nersesov  5 , Igor Anatoliyevich Anastasiy  6 , Igor Alexandrovich Karpov  7 , Olga A Golubovska  6 , Kulpash S Kaliaskarova  8 , Ravishankar Ac  9 , Sanjay Hadigal  9
Affiliations
Review

Consensus on management of hepatitis C virus infection in resource-limited Ukraine and Commonwealth of Independent States regions

Massimo Giuseppe Colombo et al. World J Gastroenterol. .

Abstract

Globally, 69.6 million individuals were infected with hepatitis C virus (HCV) infection in 2016. Of the six major HCV genotypes (GT), the most predominant one is GT1, worldwide. The prevalence of HCV in Central Asia, which includes most of the Commonwealth of Independent States (CIS), has been estimated to be 5.8% of the total global burden. The predominant genotype in the CIS and Ukraine regions has been reported to be GT1, followed by GT3. Inadequate HCV epidemiological data, multiple socio-economic barriers, and the lack of region-specific guidelines have impeded the optimal management of HCV infection in this region. In this regard, a panel of regional experts in the field of hepatology convened to discuss and provide recommendations on the diagnosis, treatment, and pre-, on-, and posttreatment assessment of chronic HCV infection and to ensure the optimal use of cost-effective antiviral regimens in the region. A comprehensive evaluation of the literature along with expert recommendations for the management of GT1-GT6 HCV infection with the antiviral agents available in the region has been provided in this review. This consensus document will help guide clinical decision-making during the management of HCV infection, further optimizing treatment outcomes in these regions.

Keywords: Antiviral agents; Commonwealth of Independent States; Genotype; Hepatitis C virus; Sustained virologic response; Ukraine.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: Colombo MG received grants/research/clinical trial support from Bristol-Meyers Squibb [Hepatology, viral hepatitis C (Daclatasvir)], Gilead Sciences [Hepatology, viral hepatitis C (Sofosbuvir)], and Merck [Hepatology, viral hepatitis C (Boceprevir)]. Colombo MG is a part of the speaker’s bureau at Bayer, Gilead Sciences, and Roche and is a consultant and advisory panel at Bayer, AbbVie, Gilead Sciences, Janssen, Merck, Roche, Mylan, and Boehringer Ingelheim. Nersesov AV supports research at Janssen, Merck, AbbVie, Abbott, and Sanofi. Nersesov AV is a part of the speaker’s bureau at Abbott, AbbVie, Bayer, Gilead Sciences, Janssen, Merck, Roche, and Sanofi and is a board member/advisory panel at Abbott, AbbVie, Gilead Sciences, Janssen, Merck, Roche, and Mylan. Ravishankar AC and Hadigal S are employees at Mylan Pharmaceuticals Private Limited. The remaining authors have no conflict of interests.

Figures

Figure 1
Figure 1
Pharmacological features of direct-acting antiviral agents available in Ukraine and some Commonwealth of Independent States regions. DAA: Direct-acting antiviral agents; CIS: Commonwealth of Independent States; HCV: Hepatitis C virus; RNA: Ribonucleic acid; Tmax: Time required to reach the peak plasma concentration of the drug; LDV: Ledipasvir; RBV: Ribavirin; SOF: Sofosbuvir; ESRD: End-stage renal disease; OD: Once-daily; CYP: Cytochrome P; MOA: Mechanism of action.
See this image and copyright information in PMC

References

    1. World Health Organization. Hepatitis C. 2018. Available from: http://www.who.int/en/news-room/fact-sheets/detail/hepatitis-c.
    1. Centers for Disease control and prevention. Hepatitis C. 2018. Accessed on: 01 August; 2018. Available from: https://www.cdc.gov/hepatitis/hcv/index.htm.
    1. Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2:161–176. - PubMed
    1. Hill AM, Nath S, Simmons B. The road to elimination of hepatitis C: analysis of cures versus new infections in 91 countries. J Virus Erad. 2017;3:117–123. - PMC - PubMed
    1. Petruzziello A, Marigliano S, Loquercio G, Cozzolino A, Cacciapuoti C. Global epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of hepatitis C virus genotypes. World J Gastroenterol. 2016;22:7824–7840. - PMC - PubMed

MeSH terms

Substances